Edition:
United Kingdom

Clovis Oncology Inc (CLVS.OQ)

CLVS.OQ on NASDAQ Stock Exchange Global Select Market

25.32USD
22 Feb 2019
Change (% chg)

$1.14 (+4.71%)
Prev Close
$24.18
Open
$24.19
Day's High
$25.40
Day's Low
$24.13
Volume
437,094
Avg. Vol
801,252
52-wk High
$65.17
52-wk Low
$11.50

Chart for

About

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine... (more)

Overall

Beta: 1.61
Market Cap(Mil.): $4,124.93
Shares Outstanding(Mil.): 48.88
Dividend: --
Yield (%): --

Financials

  CLVS.OQ Industry Sector
P/E (TTM): -- 69.44 33.70
EPS (TTM): -8.75 -- --
ROI: -72.20 8.92 14.45
ROE: -162.18 10.08 15.96

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

18 Sep 2018

Clovis Oncology, execs to pay $20 million to settle SEC charges

WASHINGTON, Sept 18 U.S. biotechnology company Clovis Oncology Inc and its Chief Executive Patrick Mahaffy and former CFO Erle Mast, will pay more than $20 million to settle charges of misleading investors about the efficacy of a cancer drug, the top U.S. securities regulator said on Tuesday.

18 Sep 2018

Earnings vs. Estimates